Damora Therapeutics, Inc.

NASDAQ: DMRA · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0001800315Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 62DQ —GM —SS 37

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ listing tenure, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$209.8M

Employees

Market cap

$1.8B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$209.8M-$209.8M2025

Operating income-$210.9M-$210.9M2025

Total assets$260.5M$260.5M2025

Liabilities$20.1M$20.1M2025

Equity$240.4M$240.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Damora Therapeutics, Inc. earned -$209.8M in FY2025 net income.

Peers · Healthcare

Agilon Health, Inc.56C UroGen Pharma Ltd.54D Mineralys Therapeutics, Inc.——Bausch Health Companies Inc.82B+

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Alnylam Pharmaceuticals, Inc.$3.7B79B+

Key facts

CEOJennifer A. Jarrett

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: DMRA

Employees7

IPO date2026-03-10

Latest filings

8-K2026-06-17 10-Q2026-05-12 8-K2026-05-04 DEF 14A2026-04-29 8-K2026-04-20 8-K2026-03-23 10-K2026-03-19 8-K2026-03-10

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.